Wael A. Alanazi, PhD
Email: waalanazi@ksu.edu.sa
Dept. of Pharmacology & Toxicology
College of Pharmacy
King Saud University
P.O. Box 2457, Riyadh, 11451, Saudi Arabia

EDUCATION:

• Ph.D. in Pharmacology, Department of Basic Pharmaceutical Science, School of Pharmacy, University of Louisiana at Monroe. (December 2016)
• B.S. Pharmaceutical Sciences, College of Pharmacy, King Saud University (KSU), Riyadh, Saudi Arabia. (January 2011)

WORK HISTORY:

• Member, Scientific Research Ethics Committee, King Saud University, Riyadh, Saudi Arabia. (September 2024 - Present).
• Chair, Graduate Students Affairs Committee, Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia. (August 2023- Present).
• Vice Chair, Disciplinary Subcommittee, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia. (November 2022- Present).
• Associate Professor, Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia. (November 2021- Present).
• Member, Pharmacy Education Unit, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia. (May 2021- Present).
• Chair, Academic Affairs Committee, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia. (October 2019- November 2020).
• Chair, Teaching Load Committee, Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia. (January 2019- September 2021).
• Assistant Professor, Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia. (February 2017- November 2021).
• Research Assistant, Department of Basic Pharmaceutical Sciences, School of Pharmacy, University of Louisiana at Monroe, Louisiana, USA. (January 2013- December 2016).
• Teaching Assistant, Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia. (December 2011- February 2017).
• Drugs Evaluator, Product Evaluation and Standard Setting Executive Directorate, Drug Sector at Saudi Food and Drug Authority (SFDA), Riyadh, Saudi Arabia. (August 2011- December 2011).

INTERNSHIPS:

• Internship, Security Forces Hospital. Riyadh, Saudi Arabia. (August 2010- October 2010).
• Internship, Pfizer Company. Riyadh, Saudi Arabia. (July 2010- August 2010).
• Internship, Community Pharmacy (Health House Pharmacies). Riyadh, Saudi Arabia. (July 2009- September 2009).

EXPERIENCES:

• Teaching Experience:

  Extensive teaching experience in biochemistry, pharmacology, and toxicology for undergraduate, graduate, and doctoral students, including:

• Undergraduate Courses:
  • Pathophysiology, Drug Action, and Therapeutics-1 (PDAT1)
  • Pharmacology I & III – Pharmacy students
  • Pharmacology in Dentistry – Dental medicine students
  • Fundamentals of Biochemistry of Diseases – Pharmacy students
  • Graduation project – Pharmacy students
• Master’s Level Courses:
  • Toxicology of Drugs of Abuse
  • Pharmacological Screening
  • Advanced Pharmacology II
  • Biochemical Toxicology
  • Physiological Chemistry
• Doctoral Level Course:
  • Drug Discovery and Development – Pharmacy PhD students
  • Research Methods in Pharmacology – Pharmacy PhD students
  • Laboratory Rotation – Pharmacy PhD students

• Research Experience:

  Comprehensive research experience with a focus on the molecular mechanisms of diabetes and its cardiovascular and renal complications. Specific expertise includes:

• Animal Models & In Vivo Studies:
  • Development of hypertensive rodent models
  • Development of hypoglycemic and hyperglycemic rodent models for acute and chronic studies
  • Proficient in drug administration via intraperitoneal, subcutaneous, and oral routes
  • Skilled in rodent surgeries including catheterization of carotid artery, jugular vein, and urinary bladder
• Analytical Techniques & Equipment:
  • Non-invasive blood pressure monitoring using CODA® High Throughput System (SBP, DBP, MAP, HR)
  • Renal microdialysis for interstitial fluid sampling
  • Electron Paramagnetic Resonance (EPR) Spectroscopy
  • Renal clearance analysis using IL943 Automatic Flame Photometer
  • Hematological analysis via PCE-210N Blood Cell Counter
  • ELISA and EIA for biomarker detection
  • Gene expression analysis using QuantStudio™ 6 Flex Real-Time PCR System
  • Protein analysis via Western blotting
  • Bioanalysis of plasma and tissue samples
• Software Proficiency:
  • CODA® Data Acquisition, Hatteras Instruments, BIOPAC MP150
  • GraphPad Prism®, GraphPad Instat
  • Gen 5™ Microplate Data Collection & Analysis Software

GRANTS & FUNDING:

• Principal investigator of research group no (ORF-2025-863) funded by the Deanship of Scientific Research at King Saud University.
• Principal investigator of research group no (RSPD2023R863) funded by the Deanship of Scientific Research at King Saud University.
• Principal investigator of research group no (RSPD2024R863) funded by the Deanship of Scientific Research at King Saud University.
• Principal investigator of research group no (IFKSUOR3-388) funded by the Deputyship for Research and Innovation, “Ministry of Education” in Saudi Arabia.
• Principal investigator of a research group funded by Diabetes Research Grant by Prince Naif Bin AbdulAziz Health Research Center at King Saud University.
• Principal investigator of research group no (RG-1441-386) funded by the Deanship of Scientific Research at King Saud University.
• Research Project Support Initiative by Prince Naif Bin AbdulAziz Health Research Center at King Saud University.
• Raed Program grant funded by the Deanship of Scientific Research at King Saud University.
• Funding for Faculty of Pharmacy by King Saud University.
• Principal Investigator for several undergraduate research projects.

SUPERVISION OF POSTGRADUATE STUDENTS:

• Master’s thesis entitled “Mechanisms Underlying Electronic and Tobacco Cigarette Smoking-Induced Hypertension: Role of Oxidative Stress” by Yazeed Alqudayri (January 2024).
• Master’s thesis entitled “In Vivo Investigation and Evaluation of Novel Cyclic-Imide Compound (5e) as a Hypoglycemic Agent in a Diabetic Rat Model” by Ali Alenezi (December 2023).
• Master’s thesis entitled “Mechanism Underlying Triple VEGFR Inhibitor Tivozanib Induced Vascular Toxicity and Hypertension: Role of Angiotensin II and Oxidative stress” by Abdulrahman Salem Alanazi (March 2023).
• Master’s thesis entitled “Role of Dapagliflozin in the Attenuation of LPS-induced Hemodynamic Disturbances and Cardiotoxicity during Euglycemic and Hyperglycemic Conditions” by Turki Fawaz Alharbi (March 2022).

AWARDS:

• First place in the Oral Presentation Award at the 13th College of Pharmacy Research Day for the research project entitled “Mechanisms Underlying Electronic and Tobacco Cigarette Smoking-Induced Hypertension: Role of Oxidative Stress” (May 2024).
• Fifth place in the Best Poster Presentation Award at the 12th College of Pharmacy Research Day for the research project entitled “Mechanisms Underlying Electronic and Tobacco Cigarette Smoking-Induced Hypertension: Role of Oxidative Stress” (May 2023).
• Sixth place in the Young Pharmacist Research Presentation Award at the 12th College of Pharmacy Research Day for the research project entitled “Dapagliflozin mitigates hypothermia and renal injury in lipopolysaccharide-induced acute inflammation independent of glycemia level” (May 2023).
• Ninth place in the Best Poster Presentation Award at the 12th College of Pharmacy Research Day for the research project entitled “Mechanism Underlying Triple VEGFR inhibitor Tivozanib-induced Vascular Toxicity and Hypertension” (May 2023).
• First place in the Best Poster Presentation Award at the Interprofessional Collaboration in Health Practice, Research and Education (ICPRE) for the research project entitled “Dapagliflozin mitigates hypothermia and renal injury in lipopolysaccharide-induced acute inflammation independent of glycemia level” (March 2023).
• The Best Research Project Award in the Drug Safety Award at Saudi Food and Drug Authority (SFDA) for the research project entitled “Angiotensin-II type 1 Receptor Blockade Prevents Tivozanib-induced Hypertension and Renal-cardiovascular Toxicity” (June 2023).
• Research Audience Choice Award in the Best Poster Presentation Award at the 11th College of Pharmacy Research Day for the research project entitled “Angiotensin-II type 1 Receptor Blockade Prevents Tivozanib-induced Hypertension and Renal-cardiovascular Toxicity” (May 2022).
• Third place in the Best Poster Presentation Award at the 11th College of Pharmacy Research Day for the research project entitled “Angiotensin-II type 1 Receptor Blockade Prevents Tivozanib-induced Hypertension and Renal-cardiovascular Toxicity” (May 2022).
• First place in the Best Poster Presentation Award at the 9th College of Pharmacy Research Day for the research project entitled “Role of renin angiotensin-II system in gefitinib-induced cardiotoxicity” (April 2019).
• Fifth place in the Best Poster Presentation Award at the 8th College of Pharmacy Research Day for the research project entitled “Role of carnitine in regulation of hypoglycemia-induced hypertension and cardiac hypertrophy” (April 2018).

PUBLICATIONS:

1. Alanazi WA, Alenezi AH, El-Nagar DM, Alanazi MM, Almutairi MM, Alaa A.‑M. Abdel‑Aziz AA, El‑Azab AS. Cyclic-imide derivative (5e) attenuates hyperglycemia in type 1 diabetic rats by protecting pancreatic cells and enhancing insulin secretion. Saudi Pharmaceutical Journal 2025, 33, 52. https://doi.org/10.1007/s44446-025-00057-9
2. Alanazi WA, Alqudayri Y, Alqahtani F, Alasmari F, El-Nagar DM. Evaluation of the Effects of Tempol on Oxidative Stress and Angiotensin-II Induced Hypertension in Mice Exposed to Nicotine from Electronic and Tobacco Cigarettes. Toxicology and Applied Pharmacology 2025, 117386.
3. Alanazi WA, Alharbi T, Bin Anzan KM, Alyahiya MK, El-Nagar DM, Alanazi MM, Almutairi MM, Alhamami HN, Albogami AM, Mohany M. The Role of Dapagliflozin in the Modulation of Hypothermia and Renal Injury Caused by Septic Shock in Euglycemic and Hyperglycemic Rat Models. Current molecular pharmacology 2024, 17, e18761429329635. https://doi.org/10.2174/0118761429329635241016054513
4. Alhamami HN, Albogami AM, Algahtani MM, Alqinyah M, Alanazi WA, Alasmari F, Alhazzani K, Alanazi AZ, Alasmari YA, Alhamed AS. The Effect of Inhibiting Hindbrain A2 Noradrenergic Neurons by 6-Hydroxydopamine on Lipopolysaccharide-treated Male Rats Autistic Animal Model. Saudi Pharmaceutical Journal 2024, 101964. https://doi.org/10.1016/j.jsps.2024.101964
5. Alhareth DY, Alanazi A, Alanazi WA, Ansari MA, Nagi MN, Ahmad SF, Attia MSM, Nadeem A, Bakheet SA, Attia SM. Carfilzomib Mitigates Lipopolysaccharide/D-Galactosamine/Dimethylsulfoxide-Induced Acute Liver Failure in Mice. Biomedicines. 2023, 11(11):3098. https://doi.org/10.3390/biomedicines11113098
6. Alshamrani AA, Al-Hamamah MA, Albekairi NA, Attia MSM, Ahmad SF, Assiri MA, Ansari MA, Nadeem A, Bakheet SA, Alanazi WA, Attia SM. Impacts of the DPP-4 Inhibitor Saxagliptin and SGLT-2 Inhibitor Dapagliflozin on the Gonads of Diabetic Mice. Biomedicines 2023, 11, 2674. https://doi.org/10.3390/biomedicines11102674
7. Algahtani MM, Ahmad SF, Alkharashi LA, Al-Harbi NO, Alanazi WA, Alhamed AS, Attia SM, Bakheet SA, Ibrahim KE, Nadeem A. Exposure to Methylmercury at Juvenile Stage Worsens Autism-like Symptoms in Adult BTBR T+tf/J Mice Due to Lack of Nuclear Factor Erythroid 2-Related Factor 2 Signaling Upregulation in Periphery and Brain. Toxics. 2023, 11, 546. https://doi.org/10.3390/toxics11060546  
8. Alanazi WA, Alharbi T, El-Nagar DM, Albogami AM, Alswayyed M. Dapagliflozin Mitigates Hypotension in Lipopolysaccharide-induced Acute Inflammation Independent of Glycemia Level. Pharmaceutics. 2023; 15(6), 1683; https://doi.org/10.3390/pharmaceutics15061683
9. Alanazi WA, Alanazi AS, El-Nagar DM, Aljuraybah AM, Alsanea S, Alharbi M. Mechanism Underlying Triple VEGFR Inhibitor Tivozanib-Induced Hypertension in Mice Model. Pharmaceuticals. 2023; 16(2):295. https://doi.org/10.3390/ph16020295
10. Alanazi WA, Alhamami HN, Alshamrani AA, Alqahtani F, Alshammari A, Alhazzani K, & Alswayyed M. Valsartan prevents gefitinib-induced lung inflammation, oxidative stress, and alteration of plasma metabolites in rats. Saudi Journal of Biological Sciences, 2023, 30. https://doi.org/10.1016/j.sjbs.2022.103522
11. Alharbi M, Alshammari A, Kaur G, Kalra S, Mehan S, Suri M, Chhabra S, Kumar N, Alanazi WA, Alshanwani AR, AL-Ghamdi AH, Narula AS, & Kalfin R. Effect of Natural Adenylcyclase/cAMP/CREB Signalling Activator Forskolin against Intra-Striatal 6-OHDA-Lesioned Parkinson’s Rats: Preventing Mitochondrial, Motor and Histopathological Defects. Molecules, 2022, 27(22): 7951. https://doi.org/10.3390/molecules27227951
12. Alanazi WA, Alhamami HN, Alharbi M, Alhazzani K, Alanazi AS, Alsanea S, Ali N, Alasmari AF, Alanazi AZ, Alotaibi MR & Alswayyed M. Angiotensin II type 1 receptor blockade attenuates gefitinib-induced cardiac hypertrophy via adjusting angiotensin II-mediated oxidative stress and JNK/P38 MAPK pathway in a rat model. Saudi Pharmaceutical Journal. 2022. https://doi.org/10.1016/j.jsps.2022.06.020
13. Alanazi MM, Elkady H, Alsaif NA, Obaidullah AJ, Alanazi WA, Al-Hossaini AM, Alharbi MA, Eissa IH, Dahab MA. Discovery of new quinoxaline-based derivatives as anticancer agents and potent VEGFR-2 inhibitors: Design, synthesis, and in silico study. Journal of Molecular Structure. 2022, 1253:132220. https://doi.org/10.1016/j.molstruc.2021.132220
14. Nadeem A, Ahmad SF, Al-Harbi NO, Sarawi W, Attia SM, Alanazi WA, Ibrahim KE, Alsanea S, Alqarni SA, Alfardan AS, Bakheet SA. Acetyl-11-keto-β-boswellic acid improves clinical symptoms through modulation of Nrf2 and NF-κB pathways in SJL/J mouse model of experimental autoimmune encephalomyelitis. International Immunopharmacology. 2022, 107, 108703. https://doi.org/10.1016/j.intimp.2022.108703
15. Sulaiman AA, Alhoshani A, Ahmad S, Peedikakkal AP, Abogosh AK, Alghanem M, Mahmoud MA, Alanazi WA, Alasmael N, Monim-ul-Mehboob M, Isab AA. Synthesis, anticancer activity and apoptosis induction of gold(I) complexes containing tris(o-methoxyphenyl)phosphane. Inorganica Chimica Acta. 2021, 527, 120567. https://doi.org/10.1016/j.ica.2021.120567
16. Alsaif NA, Taghour, MS, Alanazi, MM, Obaidullah, AJ, Alanazi WA, Alasmari A, Albassam H, Dahab MA & Mahdy HA. Identification of new [1,2,4]triazolo[4,3-a]quinoxalines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, anticancer evaluation, and in silico studies. Bioorganic & medicinal chemistry. 2021, 46, 116384. https://doi.org/10.1016/j.bmc.2021.116384
17. Alsaif NA, Elwan A, Alanazi MM, Obaidullah AJ, Alanazi WA, Alasmari AF, Albassam H, Mahdy HA, Taghour MS. Design, synthesis and molecular docking of new [1,2,4] triazolo[4,3-a]quinoxaline derivatives as anticancer agents targeting VEGFR-2 kinase. Mol Divers. 2022, 26, 1915-1932.https://doi.org/10.1007/s11030-021-10303-6
18. Alanazi MM, Eissa IH, Alsaif NA, Obaidullah AJ, Alanazi WA, Alasmari AF, Albassam H, Elkady H, Elwan A. Design, synthesis, docking, ADMET studies, and anticancer evaluation of new 3-methylquinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers. J Enzyme Inhib Med Chem. 2021, 36, 1760-1782. https://doi.org/10.1080/14756366.2021.1956488
19. Alhazzani K, Alotaibi MR, Alotaibi FN, Aljerian K, As Sobeai HM, Alhoshani AR, Alanazi AZ, Alanazi WA & Alswayyed M. Protective effect of valsartan against doxorubicin-induced cardiotoxicity: Histopathology and metabolomics in vivo study. Journal of biochemical and molecular toxicology. 2021, 35(9), e22842. https://doi.org/10.1002/jbt.22842
20. Nadeem A, Ahmad, SF, Al-Harbi NO, Ibrahim KE, Alqahtani F, Alanazi WA, Mahmood HM, Alsanea S, & Attia SM. Bruton’s tyrosine kinase inhibition attenuates oxidative stress in systemic immune cells and renal compartment during sepsis-induced acute kidney injury in mice. International Immunopharmacology. 2021, 90, 107123. https://doi.org/10.1016/j.intimp.2020.107123
21. Alanazi WA, Al-Harbi NO, Imam F, Ansari MA, Alhoshani A, Alasmari AF, Alasmari F, AlAnazi M & Ali, N. Role of carnitine in regulation of blood pressure (MAP/SBP) and gene expression of cardiac hypertrophy markers (α/β-MHC) during insulin-induced hypoglycemia: Role of oxidative stress. Experimental and clinical of pharmacology and physiology. 2020, https://doi.org/10.1111/1440-1681.13455.
22. Alasmari AF, Ali N, Alasmari F, Alanazi WA, Alqahtani F, Alharbi M, Alotaibi FM, Aldossari AA, AlSwayyed M, Alanazi MM, & Alshamrani AA. (2020). Elucidation of the Molecular Mechanisms Underlying Sorafenib-Induced Hepatotoxicity. Oxidative medicine and cellular longevity. 2020, 7453406. https://doi.org/10.1155/2020/7453406
23. Alasmari AF, Ali N, Alasmari F, Alanazi WA, AlShammari M, Al-Harbi N, AlHoshani A, As Sobeai H, AlSwayyed M, AlAnazi M & AlGhamdi N. Liraglutide attenuates gefitinib-induced cardiotoxicity and promotes cardioprotection through the regulation of MAPK/NF-kB signaling pathways. Saudi Pharmaceutical Journal. 2020, 28, 509-518.
24. Alanazi WA. Role of Carnitine on Hematological Parameters and Attenuation of Cardiac (Pro)renin Receptor and Caspase-3 Expression in Hypoglycemia-induced Cardiac Hypertrophy. International Journal of Pharmacology. 2020, 16, 191-200.
25. Nadeem A, Ahmad SF, Al-Harbi NO, El-Sherbeeny AM, Alasmari AF, Alanazi WA, Alasmari F, Ibrahim KE, Al-Harbi MM, Bakheet SA & Attia SM. Bruton's tyrosine kinase inhibitor suppresses imiquimod-induced psoriasis-like inflammation in mice through regulation of IL-23/IL-17A in innate immune cells. Int Immunopharmacol. 2020, 80, 106215.
26. Ahmad SF, Nadeem A, Ansari MA, Bakheet SA, Al-Mazroua HA, Khan MR, Alasmari AF, Alanazi WA, As Sobeai HM & Attia SM. The histamine-4 receptor antagonist JNJ7777120 prevents immune abnormalities by inhibiting RORγt/T-bet transcription factor signaling pathways in BTBR T+ Itpr3tf/J mice exposed to gamma rays. Mol Immunol. 2019, 114, 561-570.
27. Nadeem, A, Ahmad SF, Al-Harbi NO, Al-Harbi MM, Ibrahim KE, Kundu S, Attia SM, Alanazi WA & AlSharari SD. Inhibition of spleen tyrosine kinase signaling protects against acute lung injury through blockade of NADPH oxidase and IL-17A in neutrophils and γδ T cells respectively in mice. Int Immunopharmacol. 2019, 2, 39-47.
28. Alasmari F, Al-Asmari AF, Alanazi WA, Alshammari M & Alhazzani K. Neuro-inflammatory cytokines induce amyloid beta neurotoxicity through modulating amyloid precursor protein levels/metabolism. Biomed Res Int. 2018, 8 pages.
29. Imam F, Al-Harbi NO, Al-Harbi MM, Ansari MA, Al-Asmari AF, Ansari MN, Al-Anazi WA, Bahashwan S, Almutairi MM, Alshammari M, Khan MR, Alsaad AM & Alotaibi MR. Apremilast prevent doxorubicin-induced apoptosis and inflammation in heart through inhibition of oxidative stress mediated activation of NF-κB signaling pathways. Pharmacol Rep. 2018, 70, 993-1000.
30. Ahmad SF, Ansari MA, Nadeem A, Bakheet SA, Alzahrani MZ, Alshammari MA, Alanazi WA, Alasmari AF & Attia SM. Resveratrol attenuates pro-inflammatory cytokines and activation of JAK1-STAT3 in BTBR T+ Itpr3tf/J autistic mice. Eur J Pharmacol. 2018, 829.
31. Alotaibi MR, Hassan ZK, Al-Rejaie SS, Alshammari MA, Almutairi MM, Alhoshani AR, Alanazi WA, Hafez MM & Al-Shabanah OA. Characterization of Apoptosis in a Breast Cancer Cell Line after IL-10 Silencing. Asian Pac J Cancer Prev. 2018, 19, 777-783.
32. Al-Harbi NO, Nadeem A, Ahmad SF, Alotaibi MR, AlAsmari AF, Alanazi WA, Al-Harbi MM & El-Sherbeeny AM, Ibrahim KE. Short chain fatty acid, acetate ameliorates sepsis-induced acute kidney injury by inhibition of NADPH oxidase signaling in T cells. Int Immunopharmacol. 2018, 58, 24-31.
33. Fakhruddin S, Alanazi WA, Alhamami HN, Briski KP, Jackson KE. Hyperglycaemia induced by chronic i.p. and oral glucose loading leads to hypertension through increased Na+ retention in proximal tubule. Exp Physiol. 2017
34. Almutairi MM, Alanazi WA, Alshammari MA, Alotaibi MR, Alhoshani AR, Al-Rejaie SS, Hafez MM, Al-Shabanah OA. Neuro-protective effect of rutin against Cisplatin-induced neurotoxic rat model. BMC Complement Altern Med. 2017, 17, 472.
35. Fakhruddin S, Alanazi WA & Jackson KE. Development of a chronic hyperglycemic and hypertensive rat model through repetitive Intraperitoneal and oral glucose loading.  International Journal of Current Research 2017, 9, 48786-48793.
36. Fakhruddin S, Alanazi WA & Jackson KE. Diabetes-induced reactive oxygen species (ROS): Mechanism of their generation and role in Renal Injury. Journal of Diabetes Research 2017, 30 pages.
37. Alanazi WA, Uddin MB, Fakhruddin S & Jackson KE. Recurrent Insulin-Induced Hypoglycemia enhances AngII and COX2 leading to Renal PRR Expression and Oxidative Stress in the Heart and Kidney. International Journal of Medicine 2017, 5, 71-78.
38. Alanazi WA, Fakhruddin S & Jackson KE. Microdialysis Sampling of Renal Interstitial Fluid in Acute Studies. International Journal of Biology 2016, 8, 69-79.
39. Alanazi WA, Fakhruddin S & Jackson KE. The Role of Recurrent Insulin-Induced Hypoglycemia on Renal Prostanoid Production. Annual Research & Review in Biology 2016, 11, 1-9.
40. Alanazi WA, Fakhruddin S & Jackson KE. Acute Angiotensin II Infusion Promotes Local Production of Prostaglandin E2 and Reactive Species in the Renal Cortex. Innovative Journal of Medical & Health Science 2016, 146-151.
41. Prathipati P, Alanazi WA, Fakhruddin, Jackson DW & Jackson KE. Role of interstitial angiotensin II and ATP in mediating renal injury induced by recurrent insulin induced hypoglycemia. Annual Research & Review in Biology 2015, 6, 328-36.

CONFERENCES:

• Alanazi WA, Fakhruddin S & Jackson KE. Angiotensin II Induces Prostaglandin E2 Production and Oxidative Stress in the Renal Cortex. Experimental Biology (EB) Meeting, Apr. 2nd, 2016. San Diego, CA.
• Fakhruddin S, Alanazi WA & Jackson KE. Hyperglycemia Induced by Chronic Intraperitoneal and Oral Glucose Loading Leads to Hypertension through Proximal Tubule Oxidative Stress- and Angiotensin II-Mediated Na+-Retention. Experimental Biology (EB) Meeting, Apr. 22nd, 2017. San Diego, CA.